German Breast Group - Clinical Reasearch under better Conditions

"Healing through innovation, competence and partnership" has been the vision of the GBG Research Institute since its foundation in April 2003.

These cornerstones of our work allow us professional handling of clinical trials with the highest quality standards, maximum scientific independence and professional neutrality.

Clinical trials exploring new methods of treatment nowadays represent a central element of medical research. In order to achieve a balanced level of knowledge, we consider it to be indispensable that clinical trials are conducted not only by manufacturers of pharmaceutics and medicinal products, but also by academic groups.

Significant to the success of our clinical trials is our collaboration and partnership with investigators and trial staff and their trial participants, as well as the manufacturers of pharmaceutics. We have at our disposal a network of approximately 500 study sites and 1000 clinical investigators. Furthermore, we cooperate with a multitude of both national and international study groups as well as most of the pharmaceutical companies which develop drugs for the treatment of breast cancer.

 

ASCO 2015 Presentations

We hare happy to present our research at ASCO 2015.

Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.

ORAL PRESENTATION at  the Clinical Science Symposium
Authors: Sibylle Loibl, Ian Majewski, Valentina Guarneri, Valentina Nekljudova, Eileen Holmes , Emilio Bria, Carsten Denkert, Holger Eidtmann,  Christos Sortiriou, Sherene Loi, Fabrice André, Michael Untch,  Pierfranco Conte, Martine Piccart Gunter von Minckwitz,  José Baselga

Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

ORAL PRESENTATION at  the Oral Abstract Session.
Authors: Gunter von Minckwitz, Kirsten Timms, Michael Untch, Eric P. Elkin, Peter A. Fasching, Andreas Schneeweiss, Christoph T. Salat, Mahdi Rezai, Jens U. Blohmer, Dirk M. Zahm, Christian Jackisch, Bernd Gerber, Peter Klare, Sherko Kümmel, Holger Eidtmann, Stefan Paepke, Julia Reid, Valentina Nekljudova, Anne-Renee Hartman, Sibylle Loibl for the GBG and AGO-B studygroups

Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.

ORAL PRESENTATION at  the Oral Abstract Session..
Authors: David Krug, Bianca Lederer, Juergen Debus, Jens Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Claus Hanusch, Joern Hilfrich, Jens Bodo Huober, Christian Jackisch, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiss, Michael Untch, Gunter Von Minckwitz, Sibylle Loibl;

Poster: Death during study treatment: An evaluation of events in 31 German clinical trials.

Authors: Jenny Furlanetto, Gunter von Minckwitz, Bianca Lederer, Volker Möbus, Hans-Joachim Lück, Claus Hanusch, Christoph Thomssen, Michael Untch,  Sibylle Loibl

Poster: A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).

Authors: Schneeweiss A, Moebus V, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Hanusch C Hilfrich J, Huober J, Jackisch C, Paepke S, Kümmel S, Tesch H, Untch M, Loibl S, von Minckwitz G.

   

ASCO Press Release: Treatment Predictors

Abstract No: 1004, Monday June 1, 3:00 PM to 6:00 PM

Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC – Results from GeparSixto.

Abstract No: 51, Sunday May 31, 11:30 AM to 1:00 PM

PIK3CA mutation correlates with pathological complete response in primary HER2-positive breast cancer – combined analysis of 967 patients from three prospective clinical trials

Hier finden Sie die Pressemitteilung zum Vortrag beim ASCO 2015 in Chicago.

   

ASCO Press Release: Radio Therapy

Abstract No: 1008, Monday June 1, 3:00 PM to 6:00 PM

Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.

Hier finden Sie die Pressemitteilung zum Vortrag beim ASCO 2015 in Chicago.

   

GBG Trials from San Antonio 2014

M. Untch presenting at SABCS 2014

This year GBG could again present its trials successfully at the San Antonio Breast Cancer Symposium.
We are proud to present the presentaions here.

GBG32 ICE -  Efficacy
Gunter von Minckwitz: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer

GBG69 GeparSepto - Final Analysis
Michael Untch: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto)

EDUCATIONAL SESSION: HER2 Positive Breast Cancer: Insights from the Lab and Clinic
Sibylle Loibl: Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform

Poster Presentations

Sibylle Loibl: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial

Bernd Gerber: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44)

Sibylle Loibl: PD5-7 PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer

   

GAIN-2 - The trial for high-risk breast cancer

The  typical GAIN-2-patient:

  • HER2-positive or triple-negative tumor irrespective of nodal status or
  • Luminal B-tumor (ER and/or PgR-positive, HER2-negative, Ki-67 > 20%) with positive lymph nodes or
  • at least 4 affected lymph nodes.

Trial design:

More about this trial is found here.

   

more news

more News...